CLChien-Chung Lin

Chien-Chung Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chien-Chung Lin has a total of 794 co-authors. Here are the top co-authors by number of shared publications:

  • Wu-Chou Su

    Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan

    31 shared publications
  • Po-Lan Su

    Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    15 shared publications
  • Cheng-Hung Lee

    Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Medical College, National Cheng Kung University, Tainan, Taiwan

    9 shared publications
  • Chiung-Zuei Chen

    Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

    9 shared publications
  • Adeline Seow

    Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore

    8 shared publications
  • Chen Wu

    Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    8 shared publications

Latest Publications

  • Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors

    by Hung‐Chih Chiu, Chien‐Chung Lin, Chun‐Hui Lee, Yi‐Ting Yen, Yau‐Lin Tseng, Chin‐Wei Kuo, Chian‐Wei Chen, Jeng‐Shiuan Tsai, Ya‐Ting Hsu, Shih‐Chieh Chien, et al.

    Data on hepatitis B virus reactivation (HBVr) during tyrosine kinase inhibitor (TKI) therapy remain limited. We prospectively enrolled patients with chronic or resolved HBV receiving TKIs for lung cancer or chronic myeloid leukemia at one Taiwanese center (January 2023–March 2025). HBV DNA and liver enzymes were monitored 12‐weekly and HBsAg 24‐weekly. HBVr was defined by AASLD criteria, with APASL and EASL definitions applied secondarily. Among 79 patients (20 HBsAg‐positive, 59 resolved HBV), none received antiviral prophylaxis. Median follow‐up was 42 weeks (IQR, 19–65). HBVr occurred in 7 (8.9%; 95% CI, 4.4%–17.2%): 5 HBsAg‐positive (25.0%; 95% CI, 11.2%–46.9%), and 2 with resolved HBV (3.4%; 95% CI, 0.9%–11.5%). APASL and EASL definitions yielded 30.0% and 35.0% in HBsAg‐positive patients, with no additional events in resolved HBV. No HBVr‐associated hepatitis flare meeting the study definition was observed, although transient flares between assessments could not be excluded and deterioration in one fatal case was attributed clinically to sepsis. Median HBVr detection time was 19 weeks (IQR, 14–30). Week‐48 Kaplan–Meier HBVr incidence was 37.5% (95% CI, 17.0%–69.5%) in HBsAg‐positive and 5.6% (95% CI, 1.4%–21.2%) in resolved HBV (log‐rank p < 0.001); Aalen–Johansen estimates were 28.3% (95% CI, 9.5%–50.9%) and 4.3% (95% CI, 0.8%–13.2%), respectively. In exploratory Firth‐corrected regression, HBsAg positivity was associated with HBVr (HR, 6.95; 95% CI, 1.60–40.19), while osimertinib exposure was not. HBVr was common among HBsAg‐positive patients and less common but not negligible among those with resolved HBV receiving TKIs.

  • Open Access

    Assessing Time to Symptomatic Progression, a Patient-Relevant Efficacy Endpoint, in the MARIPOSA Study in Non-Small Cell Lung Cancer

    by Danny Nguyen, Se-Hoon Lee, Shun Lu, Nicolas Girard, Chien-Chung Lin, Enriqueta Felip, Andres Aguilar, Chaiyut Charoentum, Felipe Melo Cruz, Hiroaki Akamatsu, et al.

  • Open Access

    Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study

    by Chien‐Yu Lin, Po‐Lan Su, Chin‐Wei Kuo, I‐Lin Tsai, Ting‐Hui Liu, Jen Yang, Chien‐Chung Lin, Sheng‐Hsiang Lin

    Background: The discovery of driver mutations has transformed advanced non–small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)–rearranged patients achieving longest overall survival. However, the risk of cancer therapy–related cardiovascular diseases (CTRCVDs) is underrecognized, particularly comparing second‐generation ALK–tyrosine kinase inhibitors alectinib and brigatinib to the third‐generation tyrosine kinase inhibitor lorlatinib, which offers the longest progression‐free survival. We aimed to compare CTRCVDs risks among patients with lung cancer receiving ALK‐tyrosine kinase inhibitor, assess incidence trends, and identify clinical risk factors associated with ALK‐tyrosine kinase inhibitor‐related CTRCVDs. Methods: This retrospective cohort study of 946 848 adults with lung cancer (2010–2024) using TriNetX compared CTRCVDs risk in ALK‐mutated patients treated with lorlatinib versus brigatinib/alectinib. After excluding ROS1‐mutated cases and 1:1 propensity score matching, 744 patients per group were analyzed. CTRCVDs, defined as myocardial infarction, stroke, arterial embolism, or heart failure, were evaluated with Kaplan–Meier analysis and Cox proportional hazards models over 2 years. Results: Lorlatinib treatment was associated with a significantly increased risk of CTRCVDs (hazard ratio [HR], 3.00 [95% CI, 1.65–5.45]; P P =0.04), atrial fibrillation/flutter history (HR, 2.39 [95% CI, 1.13–5.07]; P =0.002), and lorlatinib use (HR, 2.42 [95% CI, 1.57–3.72]; P <0.001) as independent predictors. Conclusion: These findings underscore the importance of routine cardiovascular monitoring, particularly in older patients and those with atrial arrhythmias.


  • Open Access

    Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response

    by Hung-Chia Hsieh, Ming-Jer Young, Kuan-Yu Chen, Wu-Chou Su, Chien-Chung Lin, Yi-Ting Yen, Jan-Jong Hung, Yi-Ching Wang

    Persisting programmed cell death-1 (PD-1) signaling impairs T cell effector function, which is highly associated with T cell exhaustion and immunotherapy failure. However, the mechanism responsible for PD-1 deubiquitination and T cell dysfunction remains unclear. Here, we show that ubiquitin-specific peptidase 24 (USP24) promotes PD-1 protein stability by removing K48-linked polyubiquitin. Increased interleukin-6 level transcriptionally activates the USP24 expression, which leads to PD-1 stabilization. Furthermore, USP24 deficiency reduces PD-1 levels in CD8 + T cells and attenuates Egfr L858R -driven lung tumorigenesis in Usp24 C1695A catalytic deficient mice. Targeting PD-1 stability with the USP24-specific inhibitor USP24-i-101 boosts cytotoxic T cell activity, restrains lung tumor growth, and achieves superior therapeutic effects when combined with anti-CTLA4 immunotherapy. Clinically, patients with lung cancer exhibiting high USP24 expression in tumor-infiltrating CD8 + T cells display exhausted features and show unfavorable responses to immunotherapy. Our findings dissect the mechanism for regulating enhanced PD-1 stability in tumor-infiltrating CD8 + T cells and reveal USP24 as a potential target of antitumor immunotherapy.


  • Open Access

    Enhancing Lung Recovery: Inhaled Poly(lactic-co-glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

    by Huei-Han Zhang, Wen-Shuo Kuo, Pei-Yu Tu, Chung-Ta Lee, Hao-Chen Wang, Yu-Ting Huang, Mei-Chun Shen, Tsai-Shiuan Lin, Po-Lan Su, Jeng-Shiuan Tsai, et al.

    Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a rapidly progressing respiratory failure condition, results in a high mortality rate, especially in severe cases. Numerous trials have investigated various pharmacotherapy approaches, but their effectiveness remains uncertain. Here, we present an inhaled nanoformulation of fingolimod (FTY720)-nobiletin (NOB)- poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) with good biocompatibility and a sustained-release pharmacological effect. The formulation decreases the toxicity of FTY720 and increases the bioavailability of NOB since we use PLGA with a high biocompatibility to encapsulate FTY720 and NOB at the same time. In vitro, in comparison to treatment with the pure drug, we demonstrated that FTY720-NOB-PLGA NPs can reduce interleukin-6 (IL-6) and reactive oxygen species (ROS) release by macrophages after lipopolysaccharide (LPS) stimulation more efficiently. In vivo, we used an inhalation tower system that allowed the exposure of unanesthetized mice to aerosolized FTY720-NOB-PLGA NPs under controlled conditions. We demonstrated that inhaled FTY720-NOB-PLGA NPs can attenuate lung injury after LPS exposure by suppressing cytokine release, such as IL-6 and tumor necrosis factor-α (TNF-α). The trigger pathway of ALI, including nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and p38 mitogen-activated protein kinase, was also efficiently inhibited. Furthermore, the inhalation treatment provided a good safety profile, without detrimental effects on biochemical markers and lung function. We provided the feasibility of administering inhalation of NPs noninvasively with continuous monitoring of lung function. The aerosolized FTY720-NOB-PLGA NPs we developed show excellent promise for acute lung injury therapy in the future.


  • Open Access

    Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study

    by Qi-An Wang, I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, et al.

    Background: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. In Asian populations, epidermal growth factor receptor (EGFR) mutations are particularly prevalent, leading to the development of EGFR tyrosine kinase inhibitors (TKIs) to improve patient outcomes. While extensive research has been conducted on the prognosis of patients receiving EGFR-TKIs, the estimation of 5-year survival in this population remains an underexplored area. Objectives: This study aimed to provide real-world evidence and conduct a comprehensive analysis of the determinants influencing the 5-year survival rate in patients with EGFR-mutated NSCLC. Considering the factors identified in this study, a scoring system was developed to predict the likelihood of patients achieving this goal. Design: A retrospective cohort study utilizing a training cohort of 1,873 patients and a validation cohort of 484 patients. Methods: A logistic regression model was constructed to evaluate the weighting of factors and develop a scoring system. The Kaplan-Meier model estimated the overall survival probability, and patients were categorized into four risk groups based on their likelihood of five-year survival. The prediction performance of both the training and validation cohorts was evaluated using the area under the curve (AUC), accuracy, precision, sensitivity, specificity, and F1-score. Results: Results indicated that age > 65 years; performance score of 2-4; metastasis to the liver, brain, bone, or pleura; and poor disease control were associated with a decreased likelihood of 5-year survival. The estimated 5-year survival rate was 23.4% (odds ratio [OR]: 20.56; 95% confidence interval [CI]: 9.06-46.64; p < 0.0001), 16.1% (OR: 12.88; 95% CI: 5.82-28.49; p < 0.0001), 7.2% (OR: 5.23; 95% CI: 2.36-11.60; p < 0.0001), and 1.5% (OR: reference) for the low-risk, intermediate-risk, high-risk, and very-high-risk groups, respectively. The validation cohort further confirmed these findings, showing survival probabilities of 52.6% (OR: 96.67; 95% CI: 11.07-844.23; p < 0.0001), 21.3% (OR: 23.49; 95% CI: 3.13-176.46; p = 0.002), 14.9% (OR: 15.21; 95% CI: 2.03-114.25; p = 0.008), and 1.1% (OR: reference) for the low-risk, intermediate-risk, high-risk, and very-high-risk groups, respectively. The training cohort demonstrated an AUC of 0.79 (95% CI: 0.75-0.82) and a model quality score of 0.75, indicating good predictive performance. Calibration plots demonstrated a good fit for the scoring system. For the external validation cohort, the AUC, precision, sensitivity, and specificity were 0.71, 0.74, 0.35, 0.33, respectively. The model achieved an F1-score of 0.47, reflecting adequate performance in predicting 5-year survival probabilities. Conclusion: This study identified critical prognostic factors and developed a validated scoring system for estimating 5-year survival in patients with EGFR-mutated NSCLC receiving EGFR-TKIs. While the model demonstrated robust predictive performance within the study cohort, broader applicability beyond Taiwan may require further refinements and alternative study designs.


  • Open Access

    Cardiac Events and Survival in Patients With EGFR-Mutant Non–Small Cell Lung Cancer Treated With Osimertinib

    by Chien-Yu Lin, Wei-Ting Chang, Po-Lan Su, Chin-Wei Kuo, Jen Yang, Chien-Chung Lin, Sheng-Hsiang Lin

    Importance: Although it has been reported that osimertinib mesylate provides better survival benefits compared with first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), it remains unclear whether osimertinib is associated with more cancer therapy–related cardiac events (CTRCEs) compared with other EGFR TKIs, as does the extent of the association these adverse effects may have with overall survival. This issue is particularly critical due to the high prevalence of EGFR variants within Asian populations, including that of Taiwan.Objective: To compare CTRCEs and their association with survival in patients treated with osimertinib vs other EGFR TKIs.Design, Setting, and Participants: This cohort study was conducted at the National Cheng Kung University Hospital, a college hospital and tertiary academic referral center in Taiwan. The median follow-up duration was 23.2 (IQR, 15.2-31.5) months. A total of 401 patients with EGFR-mutant non–small cell lung cancer (NSCLC) beginning treatment with EGFR TKIs from September 1, 2019, to July 31, 2022, were retrospectively analyzed. CTRCEs included newly emerging arrhythmias, valvular heart diseases (moderate and more), myocardial infarction, and heart failure and were analyzed after adjusting for age, sex, smoking, alcohol consumption, body mass index, cardiovascular comorbidities, thoracic radiotherapy, and cardiovascular medications. Follow-up was completed January 31, 2024.Exposure: Osimertinib.Main Outcomes and Measures: The Cox proportional hazards model was used to estimate CTRCEs in patients treated with osimertinib or other EGFR TKIs. Considering that death can lower the incidence of CTRCEs, the competing risk method was used to calculate CTRCEs after adjusting for potential confounders. Multivariable Cox proportional hazard regression analysis for overall survival was used to explore whether CTRCEs were independently associated with overall survival.Results: Among the 401 patients (253 [63.1%] female; mean [SD] age, 69.2 [11.3] years), 195 (48.6%) treated with osimertinib were matched with 206 (51.4%) treated with other EGFR TKIs. Occurrence of CTRCEs in patients receiving osimertinib was significantly higher compared with patients treated with other EGFR TKIs (29 [14.9%] vs 9 [4.4%]; hazard ratio [HR], 3.37; 95% CI, 1.56-7.26; P = .002). After adjustment for relevant cardiovascular risk factors, the HR of CTRCEs was significantly higher in the group treated with osimertinib (adjusted subdistribution HR, 4.00; 95% CI, 1.81-8.85; P < .001). In addition, CTRCEs were independently associated with overall survival (HR, 4.02; 95% CI, 2.44-6.63; P < .001).Conclusions and Relevance: In this cohort study of patients with EGFR-mutant NSCLC, osimertinib was associated with a higher incidence of CTRCEs compared with other EGFR TKIs; CTRCEs were independently associated with overall survival. These findings highlight the need for ongoing cardiac monitoring in these patients, regardless of preexisting cardiac risk factors.


  • Open Access

    Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

    by Chian-Wei Chen, Jeng-Shiuan Tsai, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin

    Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and treatment discontinuation. Since programmed death-ligand 1 (PD-L1) could not serve as a predictive biomarker, we investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictive biomarker. In our previous research, we demonstrated that a low NLR could predict survival benefits when patients with high PD-L1 expression (> 50%) received chemoimmunotherapy as opposed to immunotherapy alone. In this current study, our objective is to evaluate this predictive capacity in patients with low PD-L1 expression (< 50%). A total of 142 patients were enrolled, 28 receiving combination therapy and 114 receiving chemotherapy alone. Progression-free survival (PFS) and OS were estimated using the Kaplan-Meier method and compared using the log-rank test. Patients who received combination therapy had significantly better PFS and OS than those who received monotherapy. In the subgroup of patients with low NLR, those who received combination therapy exhibited extended PFS and OS with clinical significance, which was also confirmed by multivariate Cox regression analysis. Our study demonstrates the potential use of NLR as a biomarker for predicting survival benefits when receiving combination therapy with chemotherapy and ICIs in patients with advanced NSCLC and low PD-L1 expression.


  • Open Access

    Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study

    by Chien‐Yu Lin, Chia‐Hao Hu, Chia‐Fu Hsu, Jeng‐Shiuan Tsai, Chian‐Wei Chen, Chia‐Yin Lin, Chao‐Chun Chang, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, et al.

    Background: Some prospective studies have shown that second‐generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor ( EGFR ) mutations. However, studies comparing second‐line chemotherapy efficacy between NSCLC patients with common and uncommon EGFR mutations remain rare. This retrospective study compared treatment outcomes in these patients. Methods: Patients with EGFR ‐mutated advanced‐stage NSCLC who received first‐line EGFR‐TKIs in a tertiary referral center were retrospectively reviewed between January 2010 and August 2022. Patients with a negative T790M test at disease progression who received second‐line chemotherapy were enrolled. We compared progression‐free (PFS) and overall (OS) survival between advanced NSCLC patients with common and uncommon EGFR mutations using Kaplan–Meier and log‐rank tests. Results: In total, 209 (54.8%) patients had a negative T790M mutation test and received second‐line chemotherapy, of which 192 (91.8%) had a common EGFR mutation (exon 19 deletion or exon 21 L858R substitution), and 17 (8.2%) had an uncommon EGFR mutation. Patients with common EGFR mutations had significantly longer PFS than those with uncommon EGFR mutations (4.57 vs. 2.57 months, p = 0.031). A Cox proportional hazard regression analysis controlling for potential confounding factors indicated that an uncommon EGFR mutation was an independent prognostic factor for PFS. Conclusion: This study suggests that patients with uncommon EGFR mutations have poorer chemotherapy responses and shorter survival than those with common EGFR mutations. The development of new treatment strategies for these patients remains an unmet need.